Jyothy Labs Q1 FY27: standalone PAT falls 51% YoY to ₹47.6 Cr as input costs hit margins

Jyothy Labs' standalone Q1 FY27 (quarter ended June 30, 2026) net profit fell 50.8% year-on-year to ₹47.64 Cr from ₹96.79 Cr, even as revenue from operations grew a modest 2.95% YoY to ₹773.40 Cr. Sequentially, PAT dropped 29.4% from ₹67.52 Cr in Q4 FY26 on 7.8% higher revenue — a clear case of margin-led profit erosion rather than a demand problem. EBITDA margin (PBT plus finance cost and depreciation, less other income, over revenue) compressed to 8.36% from 16.53% a year ago and 13.49% last quarter; net margin (PAT/total income) fell to 6.02% from 12.56% YoY. Basic EPS was ₹1.30 versus ₹2.64 in Q1 FY26.

The squeeze sits almost entirely on the cost-of-goods line. Cost of materials consumed plus the change in inventories — a combined proxy for net input cost — rose to 58.9% of revenue from 49.3% a year ago, confirming the crude-linked input inflation management flagged on the Q4 FY26 call. By segment, Home Care (which includes the household insecticides business) was hit hardest: segment PBT collapsed 82.4% YoY (and 71.3% QoQ) to ₹8.14 Cr on revenue of ₹280.19 Cr, with segment margin falling to 2.9% from 15.0% a year ago. Fabric Care, the largest segment, grew revenue 14.1% YoY to ₹398.89 Cr but PBT still fell 43.0% to ₹38.33 Cr on the same cost pressure. Personal Care was the one bright spot, PBT up 14.7% YoY to ₹12.67 Cr with margin expanding to 13.4% from 11.8%.

The stock went into the print at ₹193.38, down 3.3% over the past month of trading.

For context: revenue is at a 6-quarter high.

Against management's own framing from the Q4 FY26 call — cautiously optimistic on FY27 but explicitly warning of near-term margin pressure from crude-linked input inflation, with a ~4% portfolio price hike initiated in March to offset it, and improving Household Insecticides profitability called out as a specific focus area — this quarter is a mixed read: the margin-pressure warning proved accurate and then some, but the stated aim of improving Household Insecticides/Home Care profitability moved sharply in the wrong direction instead, so the guidance is best read as missed on substance even though the caution itself was directionally correct. No Q1-specific Street consensus could be sourced; the broadest available reference (Trendlyne, 11-analyst consensus) pegs FY27 revenue growth at 6.7% and full-year PAT growth at roughly flat (-0.7%) — a 50.8% YoY PAT decline in the first quarter is materially worse than that full-year bar implies, meaning the remaining three quarters now carry a disproportionate load for the full-year number to hold.